SCHEMBL7192154

SCHEMBL7192154

CCOC(=O)C(Cc1cccc([N+](=O)[O-])c1)NC(=O)CCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
LMNA P02545 2/20 0.53
MAPT P10636 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
AGTR1 P30556 1/20 0.49
HTT P42858 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
POLB P06746 1/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7193890 0.87 HIF1A (0.49) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL6751575 0.85 TACR1 (0.51) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL27462559 0.85 TACR1 (0.51) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL6370800 0.85 TACR1 (0.51) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL23169896 0.85 ALDH1A1 (0.62) ALDH1A1MAPTPOLBTP53
SCHEMBL6776257 0.84 TRPV1 (0.53) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL7194459 0.82 ALDH1A1 (0.52) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL1491327 0.81 ITGA4 (0.61) MAPTMEN1KMT2ACYP2D6CYP2C9
SCHEMBL1491323 0.81 ITGA4 (0.61) MAPTMEN1KMT2ACYP2D6CYP2C9
SCHEMBL4733108 0.81 ITGA4 (0.50) ALDH1A1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6589972-B2 Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects BAYER AKTIENGESELLSCHAFT (DE) 2003-07-08 US disclosed
EP-1147079-A2 BETA-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS Bayer Aktiengesellschaft (DE) 2001-10-24 EP disclosed
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists SCHOOP ANDREAS (DE) 2001-10-18 US disclosed
US-6291503-B1 β-phenylalanine derivatives as integrin antagonists BAYER AKTIENGESELLSCHAFT (DE) 2001-09-18 US disclosed
WO-2000041469-A2 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists ITGB4, ITGA4, ITGB2 ALDH1A1 2010/4885LMNA 2949/4885MAPT 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.